B-cell Malignancy clinical trials at UCSD

1 research study open to eligible people

Expansion Study of BGB-16673 in Patients With B-Cell Malignancies
open to eligible people ages 18 years and up
Study consists of two main parts to explore BGB-16673 recommended dosing, a part 1 monotherapy dose finding comprised of monotherapy dose finding and monotherapy safety expansion of selected doses, and a part 2 (cohort expansion cohorts)
La Jolla, California and other locations

Last updated: August 23, 2023